AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 6-KAUG 122 min read$PYPD

PolyPid Ltd. (PYPD): Financial results for Q2 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Co

Original reporting
SEC EDGAR 6-K
Published Aug 12, 2026, 11:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 6:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$PYPD
Bullish
high confidence
Mentioned
$PYPD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$PYPDBullishHigh
01

Why it matters

The combination of an FDA priority review and a $30M upfront partnership payment provides both regulatory validation and immediate liquidity, likely driving short‑term price appreciation.

02

Market read

First‑report earnings and regulatory news for a small‑cap biotech, offering a clear catalyst for traders.

03

What to watch

The upcoming EMA MAA filing and potential competition in SSI prevention could temper long‑term upside.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

PolyPid is a Nasdaq‑listed biotech transitioning to commercial stage with its D‑PLEX₁₀₀ product for surgical site infection prevention.

Company-level read

Ticker impact

$PYPDBullishHigh confidence
Context

PolyPid reported Q2 2026 results, FDA accepted its NDA with priority review and announced a $30M upfront partnership with Azurity.

Expected impact

Potential short-term upside of 10-15% as investors price in the priority review and partnership cash.

Evidence & confidence

FDA priority review accelerates market entry; $30M cash reduces financing risk and signals strong commercial prospects.

Market effects

Sector

Biotech sector may see increased interest in companies with FDA priority reviews and partnership models.

Regional

U.S. and Canadian markets could see modest gains in healthcare stocks following the partnership announcement.

Global

Highlights the growing importance of specialty pharma collaborations for commercial-stage biotech firms.

Counterpoint

What could challenge this read

If the FDA later raises concerns or the partnership fails to meet milestones, the stock could face a sharp correction.

Key entities

  • company
    PolyPid Ltd.

    Biopharma developing D‑PLEX₁₀₀.

  • partner
    Azurity Pharmaceuticals

    Private specialty pharma partner providing upfront payment and commercialization rights in U.S. and Canada.

Read at source← All news

Related articles

OCT 1
$PYPDHighAI 8/10

European Medicines Agency Validates PolyPid’s Marketing Authorization Application for D-PLEX₁₀₀

PolyPid's (PYPD) Marketing Authorization Application for D-PLEX₁₀₀, a drug to prevent post-abdominal surgery infections, has been validated by the European Medicines Agency. The application is now under formal review. The FDA is also reviewing D-PLEX₁₀₀ under Priority Review with a PDUFA goal date of November 28, 2026. The drug showed a 60% relative risk reduction in surgical site infections in a Phase 3 trial.

globenewswire.com2 min
AUG 19
HighAI 8/10

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid (PYPD) reported Q2 2026 milestones: FDA accepted its NDA for D-PLEX100 with Priority Review, setting a PDUFA goal date of November 28, 2026. The company also signed a $320M+ commercialization deal with Azurity Pharmaceuticals for the U.S. and Canada, including upfront payments, milestones, and royalties. PolyPid plans to submit an MAA to the EMA in Q3 2026 and expects a U.S. launch in early 2027.

yahoo.com3 min
AUG 14
$PYPDMed

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid said the FDA accepted its D-PLEX100 NDA with Priority Review and no filing issues, targeting a PDUFA date of Nov. 28, 2026. It signed an exclusive U.S. and Canada commercialization deal with Azurity, including upfront and tiered royalties plus a transfer price for retained manufacturing units. PolyPid expects a U.S. launch in early 2027 and $30M in milestone payments.

yahoo.com6 min
AUG 12
$PYPDHighAI 9/10

PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Ltd. (Nasdaq: PYPD) said the FDA accepted its D-PLEX100 NDA for priority review for preventing surgical site infections in abdominal colorectal surgery, with a PDUFA goal date of Nov. 28, 2026. PolyPid entered an exclusive U.S. and Canada commercialization partnership with Azurity, receiving $30 million upfront and near-term milestones, plus tiered mid-teen to mid-twenties royalties. Q2 2026 net loss was $7.8M.

finanznachrichten.de7 min